CMS BALANCE Model The BALANCE Model (announced December 23, 2025) could expand GLP-1 coverage through participating Medicare Part D and Medicaid plans
Are compounded GLP-1 medications FDA-approved, according to this post
The diacid, as distinct from the monoacid used in liraglutide, gives a stronger and more sustained albumin interaction
Excellent for anti-aging, longevity, and wellness routines
Highlights of Prescribing Information: Qsymia (phentermine and topiramate extended-release capsules), for oral use
Importantly, the manufacturer has published a specific switching protocol outlining how patients can move from injectable Wegovy to oral Wegovy